The tool in question is the STAM3P score, first developed to identify patients whose rapidly progressive dementia is likely to have a treatment-responsive cause at their very first clinical presentation. The acronym captures seven clinically accessible features, each worth one point: seizures, a disease-associated tumor, age of onset of fifty years or younger, mania, magnetic resonance imaging findings suggestive of autoimmune encephalitis, movement disorders, and cerebrospinal fluid pleocytosis of at least ten cells per cubic millimeter. None of these features requires exotic technology; they can be gathered from the history, examination, standard MRI, and a routine lumbar puncture. Until now, however, the score’s performance had been evaluated in only a single United States-based cohort, leaving open the question of whether it would hold up in different patient populations and health care systems.

To answer that question, an international team led by researchers from Erasmus University Medical Center in the Netherlands, together with colleagues at Washington University in St. Louis and Mayo Clinic in Florida, tested the original score in an independent Dutch cohort and then asked whether it could be improved. Their reasoning was grounded in prior observations that treatment-responsive forms of rapidly progressive dementia tend to declare themselves faster than untreatable ones. Dementia that reaches diagnostic threshold within three months of symptom onset, they hypothesized, might itself be a marker of a reversible process. The Dutch cohort comprised 147 adults who developed dementia within one year of symptom onset and were enrolled prospectively across multiple centers between 2019 and 2024. The comparison group was the original American cohort of 155 patients enrolled from 2016 to 2022. Patients with obvious causes such as stroke, traumatic brain injury, or infection were excluded from both studies, and final diagnoses were assigned using established criteria by three neurologists reviewing each case.

The composition of the combined cohort of 302 patients underscores why this work matters. Sixty percent of all patients, 181 individuals, had a potentially treatment-responsive cause of their dementia. Autoimmune encephalitis alone accounted for 109 cases, or 36 percent, while inflammatory central nervous system disorders accounted for another 28. On the untreatable side, neurodegenerative diseases made up 18 percent and Creutzfeldt-Jakob disease 14 percent. In the Dutch cohort specifically, 65 percent of patients had a treatment-responsive diagnosis, a slightly higher proportion than the 55 percent seen in the American cohort, though the difference was not statistically significant. Neurodegenerative diseases were less frequent in the Dutch group, at 14 percent versus 22 percent, a difference the authors attribute in part to differing referral patterns and cohort definitions.

The statistical case for adding a time-based feature was strong. Dementia within three months of symptom onset occurred in 56 percent of patients with treatment-responsive diagnoses but only 31 percent of those with non-responsive causes, a highly significant difference. In multivariable logistic regression that accounted for the original STAM3P features, the three-month criterion carried an odds ratio of 3.09 for treatment-responsiveness, with a 95 percent confidence interval of 1.60 to 5.97. The investigators therefore created a modified score, dubbed STAM3mP, in which rapid progression to dementia within three months counts as an eighth point alongside the original seven features. They then compared the diagnostic performance of the two scores using area under the receiver operating characteristic curves, assessed with the DeLong test, and accuracy at established cutoffs, assessed with McNemar’s test.

The results in the Dutch validation cohort were encouraging. The area under the curve rose from 0.79 for the original score to 0.83 for the modified version, and accuracy improved significantly at cutoffs of two or more points, from 63 to 76 percent, and three or more points, from 44 to 56 percent. Most importantly, sensitivity increased across every cutoff value, meaning the modified score caught more of the patients whose dementia was actually treatable. A threshold of one or more STAM3mP features identified 96 percent of the 95 Dutch patients with treatment-responsive causes, at a specificity of 37 percent. In the American cohort, the overall discrimination was similar for both scores, at 0.88, but sensitivity again improved markedly at higher cutoffs, rising from 62 to 83 percent at the two-point threshold and from 26 to 44 percent at the three-point threshold. The price of this heightened sensitivity was a drop in specificity, from 62 to 41 percent at the one-point cutoff and from 93 to 83 percent at two points, a trade-off the authors argue is justified.

That argument rests on the consequences of a missed diagnosis. Autoimmune encephalitis and related inflammatory disorders can mimic prion disease and neurodegenerative dementia, and pathologically confirmed cases of autoimmune encephalitis in patients initially suspected of having Creutzfeldt-Jakob disease are well documented. When the modified score was applied to the combined cohort, the presence of at least one feature showed its highest sensitivity in patients with autoimmune encephalitis at 99 percent, toxic or metabolic causes at 94 percent, and inflammatory central nervous system disorders at 89 percent. Of the 248 patients with a score of one or more, 138 met criteria for possible autoimmune encephalitis, and 72 percent of those were ultimately confirmed to have the condition. Eight additional patients with autoimmune encephalitis were identified only after an elevated score prompted autoantibody testing, illustrating how the score can redirect the diagnostic pathway toward the right laboratory studies.

At the upper end of the scale, the modified score becomes not just a screening tool but a potential trigger for treatment. Among the 73 patients with three or more STAM3mP features, 84 percent were diagnosed with autoimmune encephalitis or another inflammatory central nervous system disorder, conditions that typically warrant immunotherapy. Only three patients with Creutzfeldt-Jakob disease reached that threshold, and even their features, such as mild pleocytosis that normalized on repeat lumbar puncture, illustrate the diagnostic noise the score must filter. With specificity of 98 percent at the three-point cutoff in the combined cohort, the authors suggest that such patients may be candidates for prompt initiation of empiric immunomodulatory therapy, provided that conditions in which immunotherapy could be harmful, such as central nervous system infection, lymphoma, or sarcoidosis, have been reasonably excluded. They also caution clinicians to watch for radiological red flags on MRI, including persistent enhancement, restricted diffusion, and mass effect, which can signal mimics of autoimmune encephalitis rather than the disease itself.

The study team proposes a practical, tiered algorithm. A score of one or more should prompt extended diagnostic workup, individualized to the patient, which may include neuronal autoantibody testing in serum and cerebrospinal fluid, additional neuroimaging and body imaging such as PET, electroencephalography, and in selected cases brain biopsy. A score of two or more raises the possibility of preliminary treatment when an autoimmune or inflammatory cause is suspected, while a score of three or more supports both further testing and early immunotherapy. The clinical criteria for autoimmune encephalitis performed well in this study, with sensitivity above 90 percent, and the authors recommend applying them sequentially after the score, using the STAM3mP as the initial filter and the criteria to guide the next steps. The score’s tumor component also carries a caveat: if initial screening is negative, detection of high-risk tumor-associated autoantibodies still warrants comprehensive and repeated tumor surveillance.

For a syndrome in which every week of delay narrows the window for recovery, a tool that costs nothing, requires no new tests, and can be computed at the bedside represents a meaningful advance. By validating the original STAM3P score in an independent European cohort and showing that a single, easily ascertained feature, the speed of progression to dementia, meaningfully improves its ability to detect treatable disease, the researchers have given neurologists a sharper instrument for one of medicine’s most time-sensitive diagnoses. The trade-off of more false positives, they contend, is one worth making when the alternative is a missed autoimmune encephalitis progressing irreversibly toward what looks like untreatable dementia.

Subject of Research: Validation and modification of the STAM3P clinical scoring tool for early recognition of treatment-responsive rapidly progressive dementia

Article Title: Early Recognition of Treatment‐Responsive Rapidly Progressive Dementia: The Modified STAM3mP Score

Article References: van Steenhoven, R. W., Satyadev, N., Bastiaansen, A. E. M., Piura, Y. D., Kerstens, J., Crijnen, Y. S., Brenner, J., Brand, T., Bienfait, T. M., Veenbergen, S., de Vries, J. M., de Jong, F. J., Dopper, E. G. P., Smitt, P. A. E. S., Seelaar, H., Day, G. S., & Titulaer, M. J. (2026). Early Recognition of Treatment‐Responsive Rapidly Progressive Dementia: The Modified STAM3 m P Score. Annals of Clinical and Translational Neurology, 13(9), 1956-1960. https://doi.org/10.1002/acn3.70434

Image Credits: AI Generated

DOI: 10.1002/acn3.70434

Keywords: rapidly progressive dementia, STAM3mP score, autoimmune encephalitis, diagnostic score, immunotherapy, Creutzfeldt-Jakob disease, cerebrospinal fluid, neurology, dementia, clinical validation, neuroinflammation, early diagnosis

Rapidly progressive dementia traditionally presented a diagnostic enigma, given its heterogeneous manifestations and overlapping clinical features that often mimicked other neurological disorders. Lei et al.’s review meticulously compiles and analyzes an extensive body of literature, providing clinicians and researchers with a clearer framework to understand the multifactorial nature of RPD. The authors emphasize that while prion diseases were historically the prime suspects in RPD cases, a growing array of alternative etiologies now demands consideration, reshaping diagnostic and therapeutic approaches.

The systematic review underscores how autoimmune encephalopathies have emerged as pivotal contributors to RPD in recent reports. These conditions, characterized by the production of autoantibodies against neuronal surface or synaptic proteins, can provoke rapidly worsening cognitive dysfunction but are potentially reversible with timely immunotherapy. The identification of autoantibody-related RPD represents a paradigm shift, highlighting the importance of early immunological screening as part of the diagnostic algorithm.

In parallel, infectious causes remain critical in the differential diagnosis, notably viral encephalitis caused by herpes simplex virus, progressive multifocal leukoencephalopathy due to JC virus, and other neurotropic infections inducing brisk cognitive decline. The review sheds light on the necessity for rapid cerebrospinal fluid analysis and advanced neuroimaging modalities to detect these infections before irreversible brain damage occurs.

Lei and colleagues also explore neurodegenerative etiologies beyond classic prionopathies, such as Alzheimer’s disease, frontotemporal lobar degeneration, and Lewy body dementia, which may present atypically with accelerated progression. The molecular pathologies underpinning these diseases—aberrant amyloid beta, tau, or alpha-synuclein aggregation—intersect with diverse clinical phenotypes that challenge straightforward diagnosis. The authors advocate for refined biomarker panels and positron emission tomography imaging to discern these aggressive neurodegenerative forms.

Metabolic and toxic causes, while less frequently encountered, are not to be overlooked. Conditions including hepatic encephalopathy, rapidly evolving vitamin deficiencies, and medication-induced cognitive disturbances can precipitate rapid dementia syndromes. The review emphasizes the critical role of comprehensive metabolic panels and medication reconciliations in the initial workup to exclude reversible contributors.

Paraneoplastic neurological disorders, driven by remote immune responses against malignancies, are another significant class explored. The authors delineate how antibodies targeting neuronal antigens elicited by underlying cancers—such as small cell lung carcinoma—can manifest with RPD, necessitating thorough oncological evaluations alongside neurological assessments.

The review carefully addresses diagnostic challenges and proposes an integrative algorithm that incorporates clinical history, neurological examination, serological testing, cerebrospinal fluid analysis, neuroimaging, and histopathological confirmation when clinically indicated. This multidimensional approach facilitates earlier and more accurate diagnosis, which is paramount for prognosis and therapeutic intervention.

Importantly, Lei et al. highlight recent advances in molecular diagnostic techniques, including next-generation sequencing and proteomic analyses of cerebrospinal fluid, which have revolutionized the ability to identify novel and rare causes of RPD. These technologies promise to unveil previously unrecognized pathogenetic mechanisms and tailor precision medicine strategies.

The review also discusses the implications of emerging therapeutic modalities, ranging from immunomodulatory treatments for autoimmune etiologies to antiviral agents targeting infectious causes, and disease-modifying therapies aimed at neurodegenerative processes. The authors propose that early intervention within narrow therapeutic windows could alter the grim natural history traditionally associated with rapidly progressive dementias.

Ethical considerations and challenges in clinical trials for RPD are also examined, given the rapid cognitive decline and high mortality rates that complicate patient recruitment and longitudinal follow-up. The authors advocate for collaborative international registries and biobanks to accelerate research and therapeutic development.

The systemic impact of accurate diagnosis on patient management and family counseling is profound. Understanding the diverse etiologies equips healthcare providers to offer realistic prognostic information, establish supportive care frameworks, and inform genetic counseling when hereditary factors are implicated.

Lei et al. conclude by emphasizing the dynamic landscape of rapidly progressive dementia research, spurred by technological and conceptual advances. Their comprehensive synthesis not only serves as a vital guide for clinicians worldwide but also sets a robust agenda for future investigative efforts to unravel the complexities of these devastating disorders.

This landmark review signifies an inflection point in dementia care, underscoring that rapid cognitive decline is not a monolithic entity but a spectrum of disorders demanding nuanced diagnostic acumen and innovative therapeutic strategies. Such insights will undoubtedly catalyze more effective management protocols and improve outcomes for patients afflicted by this formidable syndrome.

Subject of Research: Rapidly progressive dementia and its evolving etiologies

Article Title: The evolving etiologies of rapidly progressive dementia: a systematic review

Article References: Lei, MH., Cao, LJ., Liu, R. et al. The evolving etiologies of rapidly progressive dementia: a systematic review. Transl Psychiatry (2025). https://doi.org/10.1038/s41398-025-03777-7

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41398-025-03777-7